The Glimpse Group (NASDAQ:VRAR – Get Free Report) and Axe Compute (NASDAQ:AGPU – Get Free Report) are both small-cap technology companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.
Profitability
This table compares The Glimpse Group and Axe Compute’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| The Glimpse Group | -50.18% | -24.98% | -21.99% |
| Axe Compute | -7,769.61% | -5,090.33% | -530.79% |
Analyst Recommendations
This is a summary of recent recommendations and price targets for The Glimpse Group and Axe Compute, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| The Glimpse Group | 1 | 0 | 1 | 0 | 2.00 |
| Axe Compute | 1 | 0 | 0 | 0 | 1.00 |
Volatility and Risk
The Glimpse Group has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, Axe Compute has a beta of 3.44, suggesting that its stock price is 244% more volatile than the S&P 500.
Institutional & Insider Ownership
21.4% of The Glimpse Group shares are held by institutional investors. Comparatively, 9.0% of Axe Compute shares are held by institutional investors. 17.1% of The Glimpse Group shares are held by insiders. Comparatively, 1.2% of Axe Compute shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares The Glimpse Group and Axe Compute”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| The Glimpse Group | $9.49 million | 2.01 | -$2.55 million | ($0.18) | -5.02 |
| Axe Compute | $120,000.00 | 963.25 | -$233.10 million | ($8.18) | -1.23 |
The Glimpse Group has higher revenue and earnings than Axe Compute. The Glimpse Group is trading at a lower price-to-earnings ratio than Axe Compute, indicating that it is currently the more affordable of the two stocks.
Summary
The Glimpse Group beats Axe Compute on 11 of the 14 factors compared between the two stocks.
About The Glimpse Group
The Glimpse Group, Inc., a virtual reality (VR) and augmented reality (AR) platform company, provides enterprise-focused software, services, and solutions in the United States. It offers QReal, a software that creates and distributes photorealistic 3D interactive digital models and experiences in AR; Immersive Health Group, a VR/AR platform for evidence-based and outcome driven healthcare solutions; and Foretell Reality, a social VR platform for behavioral health, support groups, collaboration, and soft skills training. The company also provides Glimpse Turkey for developing and creating 3D models for QReal; XR Terra that provides immersive technologies for teaching courses and training; Sector 5 Digital for corporate immersive experiences and events; PulpoAR, an AR try-on technology that targets the beauty and cosmetics industry; and Brightline Interactive, which offers immersive and interactive experiences, training scenarios, and simulations for government and commercial customers. The company was incorporated in 2016 and is headquartered in New York, New York.
About Axe Compute
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient’s body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.
Receive News & Ratings for The Glimpse Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Glimpse Group and related companies with MarketBeat.com's FREE daily email newsletter.
